GMDP - a promising orally active immunomodulator Sandra MacPherson Newsletter Article 21 February 2013 Pages: 3 - 4
Ribavirin recommendations change - use is now discretionary Newsletter Article 21 February 2013 Pages: 5 - 5
Symptom checklists vital for comprehensive QOL assessment Newsletter Article 21 February 2013 Pages: 7 - 7
Home IV antibacterial therapy: benefits outweigh risks Newsletter Article 21 February 2013 Pages: 8 - 8
Dexniguldipine: low bioavailability, but tumour regression possible Newsletter Article 21 February 2013 Pages: 8 - 8
Immunobiological approaches to treating asthma & allergic disease Gill Higgins Newsletter Article 21 February 2013 Pages: 9 - 10
Total triglyceride levels reduced with atorvastatin Newsletter Article 21 February 2013 Pages: 11 - 11
d-Sotalol preferred to other class III antiarrhythmics Newsletter Article 21 February 2013 Pages: 12 - 12
Reassortant vaccines protect against severe rotavirus infection Newsletter Article 21 February 2013 Pages: 12 - 12
Photodynamic therapy has advantages for oesophageal cancer Newsletter Article 21 February 2013 Pages: 13 - 13
Sparfloxacin effective for community-acquired pneumonia Newsletter Article 21 February 2013 Pages: 13 - 13
Betacarotene supplements ineffective against lung cancer Newsletter Article 21 February 2013 Pages: 14 - 14
Paclitaxel & vinorelbine: will this combination improve cancer therapy? Robert H Carlson Newsletter Article 21 February 2013 Pages: 15 - 16
Low dose hydrochlorothiazide does not control hypertension in the elderly Newsletter Article 21 February 2013 Pages: 16 - 16
Individualised MOPP/ABVD not recommended for Hodgkin’s disease Newsletter Article 21 February 2013 Pages: 17 - 17
Losartan potassium helps reduce severe hypertension Newsletter Article 21 February 2013 Pages: 17 - 17
The effect of clinical trials on medical practice for MI Newsletter Article 21 February 2013 Pages: 18 - 18
Effect of measles antibody titres on vaccination response Newsletter Article 21 February 2013 Pages: 20 - 20
Measure hormone levels 2 weeks after OC withdrawal Newsletter Article 21 February 2013 Pages: 20 - 20
Cyproterone - risk for hepatic cancer not increased Newsletter Article 21 February 2013 Pages: 20 - 20